![Kathryn Haviland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Haviland
Voorzitter bij
FULCRUM THERAPEUTICS, INC.
Vermogen: 161 755 $ op 31-05-2026
Profiel
Kathryn Haviland is lid van de raad van bestuur van Fulcrum Therapeutics, Inc. en Chief Operating Officer bij Blueprint Medicines Corp., lid van de Harvard Business School Health Industry Alumni Association en lid van de Biopharma Executive Council. Haviland was voorheen Vice President-Rare Diseases bij Idera Pharmaceuticals, Inc., Head-Commercial Development bij Sarepta Therapeutics, Inc. en Executive Director-Commercial Development bij PTC Therapeutics, Inc. Zij behaalde een bachelor aan de Wesleyan University en een MBA aan de Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-06-2026 | 7.437 ( 0,01% ) | 161 755 $ | 31-05-2026 | |
| 31-03-2026 | 0 ( -.--% ) | - $ | 31-05-2026 | |
AVALYN PHARMA INC -.--% | 30-04-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
Actieve functies van Kathryn Haviland
| Bedrijven | Functie | Begin |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Voorzitter | 10-01-2022 |
| BICARA THERAPEUTICS INC. | Directeur/Bestuurslid | 21-09-2023 |
| AVALYN PHARMA INC. | Directeur/Bestuurslid | 01-03-2026 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Corporate Officer/Principal | - |
Eerdere bekende functies van Kathryn Haviland
| Bedrijven | Functie | Einde |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Algemeen Directeur | 01-01-2026 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 01-12-2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01-04-2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01-06-2012 |
Opleiding van Kathryn Haviland
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
74
Eerstegraads connecties
11
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 11 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Commercial Services |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
